Clinical Trials Logo
  1. Home
  2. Advanced Breast Carcinoma
  3. NCT06243432

Estrogen Receptors and HER2 Levels' Expression in Luminal Metastatic Breast Cancer — CYCLHER  

Advanced Breast Carcinoma Clinical Trial

Official title:
Estrogen Receptors and HER2 Levels' Expression in Luminal Metastatic Breast Cancer: Correlation to Therapeutic Efficacy of Cycline-Dependent Kinase Inhibitors(CDK4/6) as First Line Treatment. CYCLHER Study

Clinical Trial Summary

CYCLHER is a retrospective observational multicentric italian study aimed to evaluate the correlation between hormone receptors (HR) and HER2 immunohistochemistry (IHC) levels and treatment'response in patients affected by advanced breast cancer treated with first line CDK4/6 inhibitor plus endocrine therapy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06243432
Study type Observational
Source Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Contact Alessandra Fabi, MD
Phone 0039 0630157337
Email alessandra.fabi@policlinicogemelli.it
Status Recruiting
Phase
Start date February 1, 2023
Completion date March 1, 2025
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03218826 - PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery Phase 1
Completed NCT02270372 - Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer Phase 1
Active, not recruiting NCT03281902 - Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine Therapy
Completed NCT03207529 - Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer Phase 1
Recruiting NCT04090567 - Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer Phase 2
Withdrawn NCT05238831 - SMMART Adaptive Clinical Treatment (ACT) Trial Early Phase 1
Terminated NCT02474173 - Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer Phase 1
Terminated NCT04541225 - Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors Phase 1
Recruiting NCT04704661 - Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial Phase 1
Active, not recruiting NCT03179904 - TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Active, not recruiting NCT04491942 - Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer Phase 1
Recruiting NCT05969860 - At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer Phase 2
Recruiting NCT05092373 - Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax Phase 1